Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | TILT-123 |
Synonyms | |
Therapy Description |
TILT-123 is an oncolytic adenovirus engineered to express cytokines TNF-alpha and IL-2, potentially leading to activation of the immune response, and inhibition of tumor growth when combined with immune checkpoint inhibitors (PMID: 33513935). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
TILT-123 | igrelimogene litadenorepvec|TILT 123|TILT123 | TILT-123 is an oncolytic adenovirus engineered to express cytokines TNF-alpha and IL-2, potentially leading to activation of the immune response, and inhibition of tumor growth when combined with immune checkpoint inhibitors (PMID: 33513935). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04217473 | Phase I | TILT-123 | TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma (TUNINTIL) | Active, not recruiting | FRA | 1 |